Dublin, November 6, 2023 (GLOBE NEWSWIRE) — The “China Bispecific Antibody Market and Clinical Pipeline Overview 2028” drug pipelines have been added to ResearchAndMarkets.com offer.
The bispecific antibody market is rapidly expanding, with companies like Akeso leading the way and gaining global recognition for their innovative clinical candidates.
This trend is expected to persist for the near future as more companies move into the bispecific antibody space. Additionally, China has a strong network of contract development and manufacturing organizations that are contributing to the growth of the bispecific antibody market in the country.
The ever-expanding bispecific antibody market has witnessed numerous research collaborations, clinical partnerships and licensing agreements related to bispecific antibodies over the past year. This highlights the rapid pace at which bispecific antibodies are gaining importance in the Chinese immunotherapy market.
Collaborations such as those between Biotheus and BioNTech, and Chime Biologics and Hanxbio, are excellent examples of these efforts. These collaborations facilitate the exchange of knowledge, expertise and sometimes even patented technologies and concepts, often leading to the creation of bispecific antibodies with new functionalities.
China has made significant progress in its pharmaceutical sector in recent years, paving the way for modern therapeutic approaches, including immunotherapies, to enter the domestic pharmaceutical market. Monoclonal antibodies were the first immunotherapies to be introduced to the Chinese pharmaceutical market, paving the way for the development of additional immunotherapeutic modalities.
One such modality is bispecific antibodies, which have now become a focal point in the Chinese pharmaceutical market, reflecting their global importance. Although the bispecific antibody market in China is still in its early stages, with only a few candidates approved by the NMPA, it is poised for exceptional growth in the coming years, given the extensive clinical and preclinical pipeline of bispecific antibodies under development.
The development of Cadonilimab marked a technological milestone in the Chinese pharmaceutical market, as it was the world’s first PD-1 CTLA-4 bispecific immunotherapy. Notably, Cadonilimab was fully developed by Akeso, showcasing the company’s research, development and manufacturing capabilities. Cadonilimab is indicated for the treatment of relapsed or metastatic cervical cancer and is awaiting approval by other regulatory agencies, including the FDA.
Like Cadonilimab, many other first-in-class bispecific candidates are entering clinical pipelines in China, mainly due to their unique targeting of protein combinations and the distinction of being the first to target specific protein pairs. . Technology platforms have played a crucial role in enabling companies to identify effective protein combinations and construct bispecific antibodies with binding arms tailored to their chosen epitopes.
Innovations are also emerging in the development of such platforms. For example, Alphamab’s CRIB platform, designed to overcome the chemistry, manufacturing and control challenges associated with bispecific antibody development, represents an excellent bispecific Fc-based heterodimer platform. CRIB technology is the third generation of Fc-based bispecific platforms, enabling the creation of bispecific antibodies with the same format and size as conventional antibodies. CRIB was used to develop KN026, an anti-HER2 bispecific antibody currently in early phase trials for HER2-positive solid cancers.
The emerging bispecific antibody market has attracted many investors, leading to the emergence of startups in China with innovative ideas and experienced founders. One example is Sanyou Biopharmaceuticals, which launched the “Sanyou Super Trillion Common Light Chain Antibody Discovery Platform” in June 2023.
This platform allows the generation of lead antibodies that can be transformed into bispecific antibodies with desirable properties. Sanyou offers contract research and development services, aimed at helping clients overcome the challenges of bispecific antibody drug research and development.
Highlights of the report:
- Research methodology
- Bispecific Antibody Market Opportunity in China: > USD 5 billion
- Bispecific Antibody Clinical Pipeline in China by Company, Indication and Phase
- Clinical overview of the bispecific antibody clinical pipeline: > 250 bispecific antibodies
- Chinese drug regulatory framework
- Locally developed bispecific antibodies available under license: > 50 bispecific antibodies
Key topics covered:
1. China Bispecific Antibody Market Overview
1.1 Current Scenario of China Bispecific Antibody Market
1.2 China Bispecific Antibody Market Forecast
2. Recent Collaborations and Acquisitions in China Bispecific Antibody Market
3. Chinese companies have developed bispecific antibodies available for licensing
4. China Bispecific Antibody Clinical Pipeline Landscape
4.1 By company
4.2 By indication
4.3 By patient segment
4.4 By phase
4.5 By target
5. China Bispecific Antibody Clinical Pipeline by Company, Indication and Phase
5.5 Phase II
5.6 Phase II/III
5.7 Phase III
6. Clinical overview of bispecific antibodies marketed in China
7. Chinese drug regulatory framework
7.1 Approval and regulatory bodies in China
7.2 Chinese government pharmaceutical policy framework
7.3 Provisions for registration of medicines: Order of the State Administration for Market Regulation
8. China Bispecific Antibody Market Dynamics
8.1 Market Drivers and Opportunities
8.2 Market challenges and constraints
9. Competitive landscape
9.3 Akéso Biopharma
9.4 Alphamab Oncology
9.6 Beijing Biocytogen
9.8 Beijing Mabworks Biotech
9.11 BJ Biosciences
9.12 Chia Tai Tianqing Pharmaceutical Group
9.13 Elpiscience Biopharmaceutical
9.14 EpimAb biotherapeutic products
9.15 Eucure Biopharma
9.16 FutureGen Biopharmaceuticals
9.18 Gensun Biopharma
9.19 Harbor BioMed
9.20 Biotechnology Hefei HankeMab
9.21 I-MAB Biopharma
9.22 ImmuneOnco Biopharma
9.23 Innovative organic products
9.24 L&L Biopharma
9.25 LaNova Medicines Limited
9.26 Linton Pharmacy
9.27 Lyvgen Biopharma
9.28 Nanjing leads biolabs
9.29 OriCell Therapeutic
9:30 a.m. Qilu Pharmaceutical
9.33 Shanghai Genechem
9.34 Shanghai Henlius Biotech
9.36 Immune system
9.37 TG ImmunoPharma
9.38 Xuanzhu Biopharmaceutical
9.39 YZY Biopharma
9:40 a.m. Zhejiang Shimai Pharmaceutical
For more information on this Drug Pipelines report, visit https://www.researchandmarkets.com/r/7wofcq
ResearchAndMarkets.com is the world’s leading source of market research reports and international market data. We provide you with the latest data on international and regional markets, key industries, largest companies, new products and latest trends.